The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of Lamotrigine

Disease Management

View abstract

Authors

Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux P